Pancreatic cancer laboratory tests: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}};{{PSD}}
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}};{{PSD}}
==Overview==
==Overview==
Laboratory findings in pancreatic [[cancer]]  patients are often non specific and include abnormal [[liver function tests|liver function tests,]] elevated serum bilirubin levels (conjugated and total), elevated alkaline phosphatase levels and mild normocytic normochromic anemia. Patients may have evidence of malnutrition and elevated [[CA 19-9]] levels.
Laboratory findings in [[Pancreatic cancer|pancreatic]] [[cancer]]  patients are often non specific and include abnormal [[liver function tests|liver function tests,]] elevated [[Bilirubin|serum bilirubin]] levels ([[Bilirubin|conjugated]] and total), elevated [[alkaline phosphatase]] levels and mild [[Anemia|normocytic normochromic anemia]]. Patients may have evidence of [[malnutrition]] and elevated [[CA 19-9]] levels.


==Laboratory Findings==
==Laboratory Findings==
* Routine laboratory tests in pancreatic cancer patients are often non specific.
* Routine laboratory tests in [[pancreatic cancer]] patients are often non specific.
* Common abnormalities include:  
* Common abnormalities include:  
** Elevated serum bilirubin (conjugated and total)  
** Elevated [[Bilirubin|serum bilirubin]] (conjugated and total)  
** Elevated alkaline phosphatase levels  
** Elevated [[alkaline phosphatase]] levels  
** Elevated gamma-glutamyl transpeptidase levels
** Elevated [[gamma-glutamyl transpeptidase]] levels
** Normal/elevated aspartate aminotransferase and alanine aminotransferase  
** Normal/elevated [[Aspartate transaminase|aspartate aminotransferase]] and [[Alanine transaminase|alanine aminotransferase]]
** Serum amylase and/or lipase levels are normal/elevated
** [[Amylase|Serum amylase]] and/or [[lipase]] levels are normal/elevated
** CBC shows:
** [[Complete blood count|CBC]] shows:
*** mild normocytic normochromic anemia  
*** mild [[Anemia|normocytic normochromic anemia]]
*** Thrombocytosis   
*** [[Thrombocytosis]]    
** Laboratory evidence of malnutrition:
** [[Medical laboratory|Laboratory]] evidence of [[malnutrition]]:
*** Low serum albumin  
*** Low serum [[albumin]]
*** Low cholesterol level
*** Low [[cholesterol]] level


==== CA 19-9 ====
==== CA 19-9 ====
* In cancer patients, CA 19-9 antigen is an oligosaccharide found on circulating mucins.
* In cancer patients, [[CA 19-9|CA 19-9 antigen]] is an [[oligosaccharide]] found on circulating [[Mucin|mucins]].
* CA 19-9 is elevated in case of biliary disease as it is produced within the cells of the biliary tract.  
* [[CA 19-9]] is elevated in case of [[Bile duct|biliary]] disease as it is produced within the cells of the [[Bile duct|biliary]] tract.  
* The reference range of CA 19-9 is less than 35 U/mL.
* The reference range of [[CA 19-9]] is less than 35 U/mL.
* Three fourths of the patients with pancreatic carcinoma have elevated CA 19-9 levels.  
* Three fourths of the patients with [[Pancreatic cancer|pancreatic carcinoma]] have elevated [[CA 19-9]] levels.  
* CA 19-9 value of greater than 100 U/mL is highly specific for pancreatic cancer, in the absence of intrinsic liver disease or biliary obstruction.  
* [[CA 19-9]] value of greater than 100 U/mL is highly specific for [[pancreatic cancer]], in the absence of intrinsic [[liver]] disease or [[Cholestasis|biliary obstruction]].  
Role in prognosis
Role in [[prognosis]]:
* CA 19-9 levels are of prognostic value:
* Preoperative values above 50 U/mL have higher recurrence.  
** Preoperative values above 50 U/mL have higher recurrence.
* High levels indicate poorer outcome and low chance of resectability
** High levels indicate poorer outcome and low chance of resectability
Role in treatment:
Role in treatment
* To determine the resectability potential, [[CA 19-9]] levels are used as an adjunct to [[imaging]] studies.  
* To determine the resectability potential, CA 19-9 levels are used as an adjunct to imaging studies.  
* Staging laproscopy prior to resection is not required in [[Patient|patients]] presenting with low levels of [[CA 19-9]] (< 100 IU)  as they are unlikely to have occult [[Metastasis|metastatic]] disease.  
* Staging laproscopy prior to resection is not required in patients presenting with low levels of CA 19-9 (< 100 IU)  as they are unlikely to have occult metastatic disease.  
Role in assessing response to treatment:
Role in assessing response to treatment
* A falling [[CA 19-9]] level is indicative of clinical response to [[therapy]] during treatment of [[pancreatic cancer]].  
* A falling CA 19-9 level is indicative of clinical response to therapy during treatment of pancreatic cancer.  


==References==
==References==

Revision as of 21:25, 15 November 2017

Pancreatic cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pancreatic Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pancreatic cancer laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pancreatic cancer laboratory tests

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pancreatic cancer laboratory tests

CDC on Pancreatic cancer laboratory tests

Pancreatic cancer laboratory tests in the news

Blogs on Pancreatic cancer laboratory tests

Directions to Hospitals Treating Pancreatic cancer

Risk calculators and risk factors for Pancreatic cancer laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2];Parminder Dhingra, M.D. [3]

Overview

Laboratory findings in pancreatic cancer patients are often non specific and include abnormal liver function tests, elevated serum bilirubin levels (conjugated and total), elevated alkaline phosphatase levels and mild normocytic normochromic anemia. Patients may have evidence of malnutrition and elevated CA 19-9 levels.

Laboratory Findings

CA 19-9

Role in prognosis:

  • Preoperative values above 50 U/mL have higher recurrence.
  • High levels indicate poorer outcome and low chance of resectability

Role in treatment:

  • To determine the resectability potential, CA 19-9 levels are used as an adjunct to imaging studies.
  • Staging laproscopy prior to resection is not required in patients presenting with low levels of CA 19-9 (< 100 IU) as they are unlikely to have occult metastatic disease.

Role in assessing response to treatment:

References


Template:WikiDoc Sources